Procalcitonin - potential, limitations and availability

Bacterial infections and sepsis are major problems in critically ill patients. Timely diagnosis and therapy reduce morbidity and mortality. Many studies have included the investigation of various biomarkers whose elevated concentrations can indi-cate sepsis; among them, PCT proved to be most useful.

PCT is synthesized in the thyroid gland as a prohormone of calcitonin. In healthy individuals the PCT concentration is <0.1 ng/mL.

The advantage of the PCT is a high nega-tive predictive value for the exclusion of sepsis, with the cut-off value of 0.5 ng/ml. A concentration between 2 and 10 ng/ml indicates strong sepsis, whereas a value ≥10 ng/ml is associated with septic shock. In addition to the diagnosis of sepsis, the measurement of PCT concentration is use-ful for the introduction and monitoring of antibiotic therapy, which is performed ac-cording to an algorithm based on the cut-off value for PCT.

Immunoassays are used to measure PCT concentrations in serum or plasma. It is possible to determine the concentration in whole blood by using point-of-care testing. In pathological conditions that are not associated with sepsis, PCT is useful as a prognostic indicator of disease complica-tions. Some studies suggest that PCT is a potential early indicator of acute coronary syndrome.

procalcitonin, bacterial infec-tion, sepsis, intensive care unit

1. Harbarth S, Holeckova K, Froidevaux C et al. Diagnostic value of procalcitonin, interleukin-6 and interleukin-8 in critically ill patients with suspected sepsis. Am J Resp Crit Care Med 2001; 164: 396–402.

2. Guignant C, Voirin N, Venet F et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 2009; 35: 1859–67.

3. Seligman R, Papassotiriou J, Morgenthaler NG et al. Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia. Intensive Care Med 2008; 34: 2084–91.

4. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993; 341 (8844): 515-518 PMID: 8094770.

5. Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, et al. Migration of human monocytes in re-sponse to procalcitonin. Crit Care Med 2002;30:1112-7.

6. Gilbert D. Serum procalcitonin levels. It is all about confidence. Arch Intern Med 2012;172:722-23.

7. Meisner M. Update on procalcitonin measurements. Ann Lab Med 2014;34:263-273.

8. Charles PE, Ladoire S, Aho S et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteraemia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis 2008;8:38-46.

9. Hochreiter M, Kohler T, Schweiger AM et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomised prospective controlled trial. Crit Care 2009; 13: R83.

10. de Wolf HK, Gunnewiek JK, Berk Y, van den Ouweland J, de Metz M: Comparison of a new procalcitonin assay from roche with the established method on the brahms kryptor. Clin Chem 2009, 55:1043-1044.

11. Brahms. PCT sensitive KRYPTOR Assay Characteristics. http://www.brahms-usa.com/assays (10 May 2015, date last accessed)

12. Package insert: BRAHMS PCT sensitive Kryptor – Instructions for use

13. Package insert: Elecsys BRAHMS PCT – Roche Elecsys and Cobas analyzers.

14. Package insert: ADVIA Centaur BRAHMS PCT – Siemens ADVIA Centaur analyzers.

15. Package insert: Vidas BRAHMS PCT.

16. Mofidi R, Suttie SA, Patil PV, Ogston S, Parks RW: The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. Surgery 2009, 146:72-81.

17. van Nieuwkoop C, Bonten TN, van’t Wout JW, Kuijper EJ, Groeneveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Leyten EM, van Dissel JT: Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care 2010,14:R206.

18. Hugle T, Schuetz P, Mueller B, Laifer G, Tyndall A, Regenass S, Daikeler T: Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exp Rheumatol 2008, 26:453-456.

19. Arneth B : High-Sensitivity Procalcitonin (hs-PCT): A Marker for Identification of Arteriosclerosis and Myocardial Infarction?LabMedicine 2008, 39:607-610.